Literature DB >> 34383244

KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.

Nada Assaf1, Raphael Liévin2,3, Fatiha Merabet2,3, Victoria Raggueneau4, Jenifer Osman4, Rathana Kim5,6, Francine Garnache7, Mariella D'Angiò8, Patrizia Larghero9, Claus Meyer9, Rolf Marschalek9, Philippe Rousselot2,3, Christine Terré10.   

Abstract

BACKGROUND: The detection of KMT2A gene rearrangements have an important impact on the prognosis and management of acute leukemias. These alterations most commonly involve reciprocal translocations at specific breakpoint regions within KMT2A. To date, more than 100 translocation partner genes of KMT2A have been identified, with different effects on risk stratification. METHODS AND
RESULTS: We report the case of a mature plasmacytoid dendritic cells proliferation associated with B lymphoblasts harboring a KMT2A-ARHGEF12 fusion. This rare rearrangement, resulting from a cryptic deletion on the long arm of chromosome 11, is located outside the known major and minor breakpoint regions of KMT2A, not reported to date. The review of the few cases of KMT2A-ARHGEF12 reveals the tendency of this deletion to occur in therapy related hematologic neoplasm and confer unfavorable prognosis.
CONCLUSION: This review sheds light into the rare KMT2A-ARHGEF12 fusion in leukemia. Reporting rare chimeras is essential to improve knowledge about the biological mechanism and associated clinical consequences.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  ARHGEF12; Acute lymphoid leukemia; Acute myeloid leukemia; KMT2A; Plasmacytoid dendritic cell

Mesh:

Substances:

Year:  2021        PMID: 34383244     DOI: 10.1007/s11033-021-06621-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  15 in total

1.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Authors:  Philippe Moreau; Michel Attal; Cyrille Hulin; Bertrand Arnulf; Karim Belhadj; Lotfi Benboubker; Marie C Béné; Annemiek Broijl; Hélène Caillon; Denis Caillot; Jill Corre; Michel Delforge; Thomas Dejoie; Chantal Doyen; Thierry Facon; Cécile Sonntag; Jean Fontan; Laurent Garderet; Kon-Siong Jie; Lionel Karlin; Frédérique Kuhnowski; Jérôme Lambert; Xavier Leleu; Pascal Lenain; Margaret Macro; Claire Mathiot; Frédérique Orsini-Piocelle; Aurore Perrot; Anne-Marie Stoppa; Niels Wcj van de Donk; Soraya Wuilleme; Sonja Zweegman; Brigitte Kolb; Cyrille Touzeau; Murielle Roussel; Mourad Tiab; Jean-Pierre Marolleau; Nathalie Meuleman; Marie-Christiane Vekemans; Matthijs Westerman; Saskia K Klein; Mark-David Levin; Jean Paul Fermand; Martine Escoffre-Barbe; Jean-Richard Eveillard; Reda Garidi; Tahamtan Ahmadi; Sen Zhuang; Christopher Chiu; Lixia Pei; Carla de Boer; Elena Smith; William Deraedt; Tobias Kampfenkel; Jordan Schecter; Jessica Vermeulen; Hervé Avet-Loiseau; Pieter Sonneveld
Journal:  Lancet       Date:  2019-06-03       Impact factor: 79.321

2.  Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

Authors:  Valérie de Haas; Nofisat Ismaila; Anjali Advani; Daniel A Arber; Raetasha S Dabney; Dipti Patel-Donelly; Elizabeth Kitlas; Rob Pieters; Ching-Hon Pui; Kendra Sweet; Ling Zhang
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

Review 3.  Genetic aberrations in paediatric acute leukaemias and implications for management of patients.

Authors:  Tomasz Szczepański; Christine J Harrison; Jacques J M van Dongen
Journal:  Lancet Oncol       Date:  2010-05-07       Impact factor: 41.316

4.  Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.

Authors:  P J Kourlas; M P Strout; B Becknell; M L Veronese; C M Croce; K S Theil; R Krahe; T Ruutu; S Knuutila; C D Bloomfield; M A Caligiuri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

5.  Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.

Authors:  T Burmeister; R Marschalek; B Schneider; C Meyer; N Gökbuget; S Schwartz; D Hoelzer; E Thiel
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

6.  Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

Authors:  V H J Van der Velden; L Corral; M G Valsecchi; M W J C Jansen; P De Lorenzo; G Cazzaniga; E R Panzer-Grümayer; M Schrappe; A Schrauder; C Meyer; R Marschalek; L L Nigro; M Metzler; G Basso; G Mann; M L Den Boer; A Biondi; R Pieters; J J M Van Dongen
Journal:  Leukemia       Date:  2009-02-12       Impact factor: 11.528

Review 7.  Neoplasms derived from plasmacytoid dendritic cells.

Authors:  Fabio Facchetti; Marta Cigognetti; Simona Fisogni; Giuseppe Rossi; Silvia Lonardi; William Vermi
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

8.  The MLL recombinome of acute leukemias in 2017.

Authors:  C Meyer; T Burmeister; D Gröger; G Tsaur; L Fechina; A Renneville; R Sutton; N C Venn; M Emerenciano; M S Pombo-de-Oliveira; C Barbieri Blunck; B Almeida Lopes; J Zuna; J Trka; P Ballerini; H Lapillonne; M De Braekeleer; G Cazzaniga; L Corral Abascal; V H J van der Velden; E Delabesse; T S Park; S H Oh; M L M Silva; T Lund-Aho; V Juvonen; A S Moore; O Heidenreich; J Vormoor; E Zerkalenkova; Y Olshanskaya; C Bueno; P Menendez; A Teigler-Schlegel; U Zur Stadt; J Lentes; G Göhring; A Kustanovich; O Aleinikova; B W Schäfer; S Kubetzko; H O Madsen; B Gruhn; X Duarte; P Gameiro; E Lippert; A Bidet; J M Cayuela; E Clappier; C N Alonso; C M Zwaan; M M van den Heuvel-Eibrink; S Izraeli; L Trakhtenbrot; P Archer; J Hancock; A Möricke; J Alten; M Schrappe; M Stanulla; S Strehl; A Attarbaschi; M Dworzak; O A Haas; R Panzer-Grümayer; L Sedék; T Szczepański; A Caye; L Suarez; H Cavé; R Marschalek
Journal:  Leukemia       Date:  2017-07-13       Impact factor: 11.528

9.  Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.

Authors:  Claus Meyer; Bruno A Lopes; Aurélie Caye-Eude; Hélène Cavé; Chloé Arfeuille; Wendy Cuccuini; Rosemary Sutton; Nicola C Venn; Seung Hwan Oh; Grigory Tsaur; Gabriele Escherich; Tobias Feuchtinger; Hansen J Kosasih; Seong L Khaw; Paul G Ekert; Maria S Pombo-de-Oliveira; Audrey Bidet; Bardya Djahanschiri; Ingo Ebersberger; Marketa Zaliova; Jan Zuna; Zuzana Zermanova; Vesa Juvonen; Renate Panzer Grümayer; Grazia Fazio; Gianni Cazzaniga; Patrizia Larghero; Mariana Emerenciano; Rolf Marschalek
Journal:  Leukemia       Date:  2019-03-21       Impact factor: 11.528

Review 10.  Mechanisms of epigenetic regulation of leukemia onset and progression.

Authors:  Panagiotis Ntziachristos; Jasper Mullenders; Thomas Trimarchi; Iannis Aifantis
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.